-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
What treatment can be used for patients with chronic myeloid leukemia who relapse or progress after single-agent anti-PD-1 therapy? Programmed death protein-1 (PD-1) blocking monotherapy is effective in the treatment of relapsed/refractory classic Hodgkin’s lymphoma (cHL), but some patients will be resistant to PD-1 inhibitors, and only a few patients Long-lasting relief can be obtained.
For patients with chronic myeloid leukemia who relapse or progress after single-agent anti-PD-1 treatment, there is an urgent need for an effective treatment plan.
In a test cohort study, anti-PD-1 antibody combined with DNA demethylation drug decitabine has shown effective preliminary results in patients with anti-PD-1 antibody resistance.
This article reports on the efficacy of decitabine combined with anti-PD-1 therapy in the extended cohort after a longer follow-up evaluation.
In total, a total of 51 patients (test cohort: 25, extended cohort: 26) received decitabine combined with anti-PD-1 therapy, of which 50 patients were included in the efficacy evaluation.
The objective effective rate of anti-tumor response was 52% in the test cohort (including 9 cases of complete remission [CR]; 36%) and 68% in the extended cohort (6 cases of CR; 24%).
The median progression-free survival of patients treated with decitabine combined with camrelizumab in the test cohort and the extended cohort was 20.
0 months and 21.
6 months, respectively, which was significantly longer than the median progression-free survival obtained with previous anti-PD-1 monotherapy Lifetime.
Among patients with progression-free survival after 24 months of CR, it is estimated that 78% of patients show durable remission.
After decitabine combined with camrelizumab, the increase in the ratio of peripheral memory T cells is directly related to clinical efficacy and progression-free survival.
In short, for patients with relapsed/refractory chronic myeloid leukemia who have failed PD-1 inhibitor treatment, the remission rate of decitabine combined with camrelizumab is high, and the remission lasts for a long time.
Original source: Wang Chunmeng, Liu Yang, Dong Liang et al.
Efficacy of decitabine plus anti-PD-1 camrelizumab in patients with Hodgkin lymphoma who progressed or relapsed after PD-1 blockade monotherapy.
Clin Cancer Res, 2021, 10.
1158/1078- 0432.
CCR-21-0133 For more information, please click to read the original text to download the Metz Medical APP~
For patients with chronic myeloid leukemia who relapse or progress after single-agent anti-PD-1 treatment, there is an urgent need for an effective treatment plan.
In a test cohort study, anti-PD-1 antibody combined with DNA demethylation drug decitabine has shown effective preliminary results in patients with anti-PD-1 antibody resistance.
This article reports on the efficacy of decitabine combined with anti-PD-1 therapy in the extended cohort after a longer follow-up evaluation.
In total, a total of 51 patients (test cohort: 25, extended cohort: 26) received decitabine combined with anti-PD-1 therapy, of which 50 patients were included in the efficacy evaluation.
The objective effective rate of anti-tumor response was 52% in the test cohort (including 9 cases of complete remission [CR]; 36%) and 68% in the extended cohort (6 cases of CR; 24%).
The median progression-free survival of patients treated with decitabine combined with camrelizumab in the test cohort and the extended cohort was 20.
0 months and 21.
6 months, respectively, which was significantly longer than the median progression-free survival obtained with previous anti-PD-1 monotherapy Lifetime.
Among patients with progression-free survival after 24 months of CR, it is estimated that 78% of patients show durable remission.
After decitabine combined with camrelizumab, the increase in the ratio of peripheral memory T cells is directly related to clinical efficacy and progression-free survival.
In short, for patients with relapsed/refractory chronic myeloid leukemia who have failed PD-1 inhibitor treatment, the remission rate of decitabine combined with camrelizumab is high, and the remission lasts for a long time.
Original source: Wang Chunmeng, Liu Yang, Dong Liang et al.
Efficacy of decitabine plus anti-PD-1 camrelizumab in patients with Hodgkin lymphoma who progressed or relapsed after PD-1 blockade monotherapy.
Clin Cancer Res, 2021, 10.
1158/1078- 0432.
CCR-21-0133 For more information, please click to read the original text to download the Metz Medical APP~
